Abstract
This is a discussion of the new drug approval process with emphasis on the chemistry, manufacturing and controls portions of investigational new drug (IND) applications and new drug applications (NDA). Most of that is applicable to radiopharmaceutical drugs as well as to non-radioactive drugs. There are some points that are unique to radioactive products, for example, radionuclidic and radiochemical identity and purity and specific activity. This will be little more than a cursory overview of that process.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
R.J. Bayly, E.A. Evans, and J. S. Glover, Radiopharmacy, M. Tubis and W. Wolf, Ed. J. Wiley and sons, New York, NY, 1976, pages 306–307.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sheinin, E.B. (1995). Review of Radiopharmaceutical IND’s and NDA’s. In: Emran, A.M. (eds) Chemists’ Views of Imaging Centers. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9670-4_10
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9670-4_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9672-8
Online ISBN: 978-1-4757-9670-4
eBook Packages: Springer Book Archive